Table 1. Demographic and baseline characteristics of patients.
| Case | Sex | Age | Recurrence interval | rT stag | rN stage | Histology | Neoadjuvant chemotherapy | Concurret E | IMRT prescribed dose | GTV nx | Maximal dose of GTV nx | Mean dose of GTV nx | Fractionation of GTVnx | Necrosis of nasopharyngeal mucosa | R/DM | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (years) | (months) | (Cycles) | (Gy/F) | (cm3) | (Gy) | (Gy) | (Gy) | (Yes/No) | ||||||||
| 1 | M | 55 | 120 | rT3 | rN0 | - | TP × 2+E × 2 | E × 2 | 60/32 | 75.00 | 65.07 | 61.93 | 1.94 | No | / | / |
| 2 | M | 43 | 51 | rT3 | rN0 | III | TP × 2+E × 2 | E × 2 | 62/32 | 9.40 | 65.18 | 63.98 | 2.00 | No | / | / |
| 3 | M | 44 | 51 | rT3 | rN3b | III | TP × 2+E × 2 | E × 2 | 62/32 | 25.80 | 69.27 | 65.67 | 2.05 | No | / | / |
| 4 | M | 56 | 18 | rT3 | rN1b | III | TP × 5+E × 4 | E × 2 | 64/32 | 28.40 | 69.13 | 66.24 | 2.07 | No | / | REP |
| 5 | M | 61 | 10 | rT3 | rN0 | III | PF × 2+E × 2 | E × 2 | 64/32 | 15.60 | 71.32 | 67.07 | 2.10 | No | / | / |
| 6 | M | 56 | 80 | rT4 | rN0 | III | TP × 2+E × 2 | E × 2 | 64/32 | 40.04 | 71.12 | 67.17 | 2.10 | No | / | / |
| 7 | M | 43 | 36 | rT4 | rN1b | III | TP × 3+E × 3 | E × 2 | 65/32 | 38.98 | 68.71 | 64.59 | 2.02 | No | DM | DM |
| 8 | M | 44 | 42 | rT3 | rN0 | III | TP × 2+E × 2 | E × 3 | 66/33 | 20.71 | 73.00 | 69.68 | 2.11 | No | / | / |
| 9 | M | 50 | 44 | rT3 | rN0 | III | TP × 2+E × 2 | E × 2 | 66/32 | 18.60 | 71.91 | 69.21 | 2.16 | Yes | / | Hemorrhage |
| 10 | F | 39 | 12 | rT4 | rN0 | III | TP × 2+E × 2 | E × 2 | 66/30 | 19.91 | 66.69 | 63.61 | 2.12 | Yes | / | / |
| 11 | M | 43 | 44 | rT4 | rN0 | - | TP × 2+E × 2 | E × 3 | 68/32 | 40.27 | 72.53 | 67.67 | 2.11 | No | / | / |
| 12 | F | 39 | 29 | rT4 | rN3b | - | TPF × 5 | E × 2 | 64/29 | 46.10 | 71.09 | 57.33 | 1.98 | No | / | / |
| 13 | M | 36 | 18 | rT4 | rN0 | III | TPF × 2 | E × 2 | 64/29 | 61.70 | 70.58 | 66.33 | 2.29 | Yes | / | / |
| 14 | F | 49 | 48 | rT4 | rN0 | III | TPF × 3 | E × 2 | 64/28 | 62.70 | 69.15 | 65.84 | 2.35 | No | / | / |
| 15 | M | 28 | 31 | rT3 | rN1b | III | GP × 3+PF × 3 | E × 2 | 64/30 | 47.20 | 71.08 | 64.15 | 2.14 | No | / | / |
| 16 | F | 29 | 39 | rT3 | rN3b | III | TP × 2+PF × 3+TPF × 3 | E × 1 | 66/30 | 150.60 | 75.28 | 69.75 | 2.33 | Yes | / | / |
| 17 | M | 39 | 9 | rT4 | rN1b | - | GP × 6 | E × 2 | 66/30 | 65.60 | 72.40 | 69.22 | 2.31 | Yes | R+ DM | R+ DM |
| 18 | M | 55 | 18 | rT3 | rN0 | III | TP × 2+E × 1 | / | 62/32 | 29.50 | 66.12 | 54.23 | 1.69 | No | / | / |
| 19 | F | 48 | 13 | rT4 | rN0 | - | / | E × 2 | 64/29 | 41.60 | 70.81 | 67.14 | 2.32 | Yes | / | / |
| 20 | M | 46 | 69 | rT3 | rN0 | II | / | E × 2 | 64/32 | 16.30 | 68.41 | 65.10 | 2.03 | No | / | / |
| 21 | M | 48 | 19 | rT3 | rN0 | III | / | E × 2 | 65/29 | 28.70 | 71.73 | 68.89 | 2.38 | Yes | / | / |
| 22 | M | 46 | 9 | rT3 | rN0 | III | / | E × 2 | 66/29 | 28.00 | 71.93 | 70.04 | 2.42 | No | / | / |
Abbreviations: WHO, World Health Organization; M, Male; F, Female; TP, Docetaxel + Cisplatin; Gy, Gray; F, Fractionation; GP, Gemcitabine + Cisplatin; PF, Cisplatin + 5-Flurouracil; TPF, Docetaxel + Cisplatin + 5-Flurouracil; E, Endostar, Recombinant human endostatin injection; IC, Induction chemotherapy; IMRT, Intensity-modulated radiotherapy; GTVnx, Gross tumor volume of nasopharynx; REP, Radiation Encephalopathy; R, recurrence; DM, Distance Metastasis.